Protection against lethal intra-abdominal sepsis by 1-(3-dimethylaminopropyl)-3-ethylurea

Journal of Infectious Diseases

Volumn 188, Issue 3, 2003, Pages 378-387

  Ruiz Perez, Begoña ^a,c   Cisneros, Ronald L ^a   Matsumoto, Tetsuya ^a   Miller, Robert J ^b   Vasios, George ^b   Calias, Pericles ^b   Onderdonk, Andrew B ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b GENZYME CORPORATION   (United States)

^c CHANNING LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3 DIMETHYLAMINOPROPYL) 3 ETHYLCARBODIIMIDE; 1 (3 DIMETHYLAMINOPROPYL) 3 ETHYLUREA; CARBOXYMETHYLCELLULOSE; CYTOKINE; HYALURONIC ACID; SEPRAFILM; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BACTERIUM CONTAMINATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; GEL; IMMUNITY; IMMUNOREGULATION; LETHALITY; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MALE; MORTALITY; NONHUMAN; PERITONEUM ADHESION; PERITONITIS; PRIORITY JOURNAL; RAT; SEPSIS; T LYMPHOCYTE;

ABDOMINAL ABSCESS; ADJUVANTS, IMMUNOLOGIC; ANIMALS; CARBOXYMETHYLCELLULOSE; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESCHERICHIA COLI INFECTIONS; GELS; HYALURONIC ACID; MALE; RATS; RATS, WISTAR; SEPSIS; SPLEEN; T-LYMPHOCYTES; TIME FACTORS; UREA;

EID: 0042658345     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/376556     Document Type: Article

References (32)

1. Becker JM, Dayton MT, Fazio VW, et al. Prevention of postoperative abdominal adhesions by a sodium hyaluronate-based bioresorbable membrane: a prospective randomized, double-blind multicenter study. J Am Coll Surg 1996; 183:297-306.
2. Reijnen MM, Meis JF, Postma VA, van Goor H. Prevention of intraabdominal abscesses and adhesions using a hyaluronic acid solution in a rat peritonitis model. Arch Surg 1999; 134:997-1001.
3. Diamond MP. Reduction of adhesions after uterine myomectomy by Seprafilm membrane (HAL-F): a blinded, prospective, randomized, multicenter clinical study. Seprafilm Adhesion Study Group. Fertil Steril 1996; 66:904-10.
4. Gorbach SL, Bartlett JG. Anaerobic infections. N Engl j Med 1974; 290:1177-84.
5. Hack CE, Aarden LA, Thijs LG. Role of cytokines in sepsis. Adv Immunol 1997; 66:101-95.
6. Louie TJ, Onderdonk AB, Gorbach SL, Bartlett JG. Therapy for experimental intraabdominal sepsis: comparison of four cephalosporins with clindamycin plus gentamicin. J Infect Dis 1977; 135(Suppl):S18-22.
7. Onderdonk AB, Weinstein WM, Sullivan NM, Bartlett JG, Gorbach SL. Experimental intraabdominal abscesses in rats: quantitative bacteriology of infected animals. Infect Immun 1974; 10:1256-9.
8. Onderdonk AB, Bartlett JG, Louie T, Sullivan-Seigler N, Gorbach SL. Microbial synergy in experimental intraabdominal abscess. Infect Immun 1976; 13:22-6.
9. Onderdonk AB, Kasper DL, Mansheim J, Louie TJ, Gorbach SL, Bartlett JG. Experimental animal models for anaerobic infections. Rev Infect Dis 1979; 1:291-301.
10. Weinstein WM, Onderdonk AB, Bartlett JG, Gorbach SL. Experimental intraabdominal abscesses in rats: development of an experimental model. Infect Immun 1974; 10:1250-5.
11. Tzianabos AO, Cisneros RL, Gershkovich J, et al. Effect of surgical adhesion reduction devices on the propagation of experimental intraabdominal infection. Arch Surg 1999; 134:1254-9.
12. Tzianabos AO. Polysaccharide immunomodulators as therapeutic agents: structural aspects and biologic function. Clin Microbiol Rev 2000; 13:523-33.
13. Tzianabos AO, Kasper DL, Cisneros RL, Smith RS, Onderdonk AB. Polysaccharide-mediated protection against abscess formation in experimental intra-abdominal sepsis. J Clin Invest 1995; 96:2727-31.
14. Tzianabos AO, Kasper DL, Onderdonk AB. Structure and function of Bacteroides fragilis capsular polysaccharides: relationship to induction and prevention of abscesses. Clin Infect Dis 1995; 20(Suppl 2):S132-40.
15. Tzianabos AO, Gibson FC 3rd, Cisneros RL, Kasper DL. Protection against experimental intraabdominal sepsis by two poiysaccharide immunomodulators. J Infect Dis 1998; 178:200-6.
16. Tzianabos AO, Cisneros RL. Prophylaxis with the immunomodulator PGG glucan enhances antibiotic efficacy in rats infected with antibioticresistant bacteria. Ann NY Acad Sci 1996; 797:285-7.
17. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999; 340:207-14.
18. Onderdonk AB, Cisneros RL, Hinkson P, Ostroff G. Anti-infective effect of poly-β-1,6-glucotriosyl-β-1,3-glucopyranose glucan in vivo. Infect Immun 1992; 60:1642-7.
19. Babineau TJ, Hackford A, Kenler A, et al. A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients. Arch Surg 1994; 129:1204-10.
20. Babineau TJ, Marcello P, Swails W, Kenler A, Bistrian B, Forse RA. Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients. Ann Surg 1994; 220:601-9.
21. Dellinger EP, Babineau TJ, Bleicher P, et al. Effect of PGG-glucan on the rate of serious postoperative infection or death observed after high-risk gastrointestinal operations. Arch Surg 1999; 134:997-1083.
22. Knoflach A, Azuma H, Magee C, et al. Immunomodulatory functions of low-molecular weight hyaluronate in an acute rat renal allograft rejection model. J Am Soc Nephrol 1999; 10:1059-66.
23. Remick D, Strieter R, Eskandari M, et al. Role of tumor necrosis factor in lipopolysaccharide-induced pathologic alterations. Am J Pathol 1990; 136:49-60.
24. Gerard C, Bruyns C, Marchant A, et al. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 1993; 177:547-50.
25. Marchant A, Bruyns C, Vandenabeele P, et al. Interleukin-10 controls interferon-γ and tumor necrosis factor production during experimental endotoxemia. Eur J Immunol 1994; 24:1167-71.
26. Moore KW, O'Garra A, de Wall Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Annu Rev Immunol 1993; 11:165-90.
27. Zisman DA, Kunkel SL, Strieter RM, et al. MCP-1 protects mice in lethal endotoxemia. J Clin Invest 1997; 99:2832-6.
28. Matsukawa A, Kaplan MH, Hogaboam CM, Lukacs NW, Kunkel SL. Pivotal role of signal transducer and activator of transcription (Stat)4 and Stat6 in the innate immune response during sepsis. J Exp Med 2001; 193:679-88.
29. Heidecke CD, Hensler T, Weighardt H, et al. Selective defects of T lymphocyte function in patients with lethal intraabdominal infection. Am J Surg 1999; 178:288-92.
30. Martineau L, Shek PN. Changes in circulating lymphocyte subpopulations and mitogen-stimulated response in a rat infusion model of intra-abdominal infection. Crit Care Med 2000; 28:2515-21.
31. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990; 248:1349-56.
32. Saha B, Jaklic B, Harlan DM, Gray GS, June CH, Abe R. Toxic shock syndrome toxin-1-induced death is prevented by CTLA4Ig. J Immunol 1996; 157:3869-75.